Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy

@article{Nakahara2011CurrentCI,
  title={Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy},
  author={Jin Nakahara and Michiko Maeda and Sadakazu Aiso and Norihiro Suzuki},
  journal={Clinical Reviews in Allergy \& Immunology},
  year={2011},
  volume={42},
  pages={26-34}
}
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects millions of patients worldwide. The current disease-modifying therapies (DMTs) that are widely used to treat MS only show modest effects. Because MS is a chronic disease, it is important to develop treatments that have better long-term efficacy. Recently, several new-generation DMTs have been developed, most of which target specific immune molecules based on the assumption that MS is an… 
Proteomics of a conundrum: Thoughts on addressing the aetiology versus progression of multiple sclerosis
TLDR
It is suggested that if the initiating cause of multiple sclerosis is poorly understood, then curing MS is unlikely and proteomic analysis should be applied to investigating oligodendrocyte degeneration.
Time to Revisit Non-Pharmacological Research Approaches to Ameliorate Multiple Sclerosis Symptoms
TLDR
A rationale is given for the conduction of clinical trials examining the ability of dietary changes, hyperbaric oxygen treatment and approaches to improve venous return as means to ameliorate MS.
Corrigendum to ‘Multiple sclerosis: New insights and trends’
The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis
TLDR
It has been suggested that promotion of adenosinergic system may be an important factor in MS pathophysiology and considered as promising therapeutic target for this disease.
Epigenetics of multiple sclerosis
TLDR
Three primary epigenetic mechanisms and their relation to MS susceptibility: DNA methylation, histone modifications, and post-transcriptional regulation of target genes by microRNA are studied.
Multiple sclerosis and pregnancy- treatment considerations
TLDR
In-depth research on the already available and emerging therapeutic pathways in multiple sclerosis bring hope for increasingly better results in the future in the treatment of pregnant patients with multiple sclerosis.
Multiple sclerosis and pregnancy – treatment considerations – a literature review
Multiple sclerosis is a chronic inflammatory disease which, due to the destruction of the fibres of the central nervous system in the process of demyelination, leads to numerous neurological symptoms
Immunogenicity of biopharmaceuticals in chronic inflammatory diseases
TLDR
This thesis assesses endogenous immune processes affected and evaluates laboratory methods used for monitoring immunogenicity of IFNβ and TNF-α inhibitors and validated the iLite assay using a cut-point approach designed to be more sensitive and statistically accurate.
The Relation between Age, Gender and Apoptosis Regulator FasL Gene Expression in Multiple Sclerosis Patients
TLDR
Evaluation of expression level of FasL in whole blood from patients with Relapsing-Remitting (RR) form of MS showed a clear association between decreased FasL expression in females especially older than 40 years with risk of the disease, but an exact expression– phenotype correlation was failed to draw.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 71 REFERENCES
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
TLDR
At a given time point of the disease, the patterns of demyelination were heterogeneous between patients, but were homogenous within multiple active lesions from the same patient, suggesting that MS may be a disease with heterogeneous pathogenetic mechanisms.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis
TLDR
Rituximab add-on therapy was effective based upon blinded radiologic endpoints in this phase II study and b-cell–modulating therapy remains a potential option for treatment of patients with relapsing MS with an inadequate response to standard injectable therapies.
Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis
TLDR
This review examines critically the validity that EAE is an adequate and useful animal model of MS and finds credible evidence lacking, and proposes to reconsider the utilization of EAE, especially when this model is used to define therapy.
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.
TLDR
Observations suggest an enrichment of both IL-17+CD4+ and CD8+ T cells in active MS lesions as well as an important role for IL- 17 in MS pathogenesis, with some remarkable differences from the experimental autoimmune encephalomyelitis model.
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis
TLDR
Over the past 73 years, the EAE model has proved itself remarkably useful for aiding research on MS and has led directly to the development of three therapies approved for use in multiple sclerosis.
Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis
  • David A. Brown, P. Sawchenko
  • Biology, Medicine
    The Journal of comparative neurology
  • 2007
TLDR
Systematic examination of the entire CNS supported this two‐step model of EAE pathogenesis, with inflammation and neurodegeneration commencing at similar times and affecting multiple levels of predominantly sensory central pathways, including their terminal fields.
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
TLDR
Careful examination of potential treatment-related adverse events is critical and may result in unique insights into the mechanisms of action of these novel therapeutic agents, as well as increase the understanding of the pathophysiology of the diseases currently being treated by these agents.
TNF neutralization in MS
TLDR
Lenercept failed to be beneficial, but insight into the role of TNF in MS exacerbations was gained.
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS
TLDR
Since its etiology and pathogenesis have eluded detection, it is not surprising that therapeutic attempts have been empiric and often unscientific.
Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects
TLDR
The authors claim that GTCS is erroneously evaluated either as a type of epilepsy or as any type of generalized seizures, and the QSS and TTA do not provide any recommendations regarding established documentation of harmful effects of certain AEDs.
...
1
2
3
4
5
...